Clinical Trial Update: Evaluation of the DPP-4 Inhibitor Sitagliptin in the Treatment of Non-Alcoholic Fatty Liver Disease Using MRI [Phase 4]

View source ↗

Summary

This clinical trial update reports that the Phase 4 study evaluating the DPP-4 inhibitor sitagliptin for non-alcoholic fatty liver disease in adults with type 2…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Nonalcoholic Fatty Liver Disease
• Type 2 Diabetes Mellitus

Drugs mentioned

• Januvia (sitagliptin)

Snippet

Sponsor: University of Missouri-Columbia | Conditions: Type 2 Diabetes, Non-alcoholic Fatty Liver Disease | Phase 4 | Status: WITHDRAWN